<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16261">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02895191</url>
  </required_header>
  <id_info>
    <org_study_id>UTI-2001</org_study_id>
    <nct_id>NCT02895191</nct_id>
  </id_info>
  <brief_title>The Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)</brief_title>
  <official_title>A Randomized, Blind, Placebo-controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Techpool Bio-Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Techpool Bio-Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compared with placebo, evaluate the effects and safety of Ulinastatin added to conventional
      treatment for ARDS; Evaluate the dose response relationship of Ulinastatin for ARDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After signed off the informed consent form by patient or surrogate, and after completing the
      screening phase, the patients who fulfill the inclusion and exclusion criteria will be
      randomized 1:1:1:1 to the 4 study arms. All the Patients will receive the study treatment
      drugs for 7 to 14 days. Use Day 28 of last patient as a cut-off day, Collect the follow up
      visit data on both Day 28 and Day 90 of other patients．
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of adverse events(AEs) which can not excluded relatedness with study Product</measure>
    <time_frame>Day 1 to Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of PaO2/FiO2 ratio</measure>
    <time_frame>Day 0 and Day 1 to within 24h after the last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and off ventilator</measure>
    <time_frame>Day 1 to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in the ICU</measure>
    <time_frame>Day 1 to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of pulmonary compliance</measure>
    <time_frame>Day 1 , Day 3 ,Day7 and within 24h after the last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of new organ failure</measure>
    <time_frame>Day 1 to Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of APACHEⅡ Score from baseline</measure>
    <time_frame>Day 3 ,Day7 and within 24h after the last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Murray Lung Injury Score from baseline</measure>
    <time_frame>Day 3 ,Day7 and within 24h after the last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Sequential Organ Failure Assessment (SOFA) score from baseline</measure>
    <time_frame>Day 3 ,Day7 and within 24h after the last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Day 28 , Day 90 and Day 1 to Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1- Ulinastatin 4.8 million units per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2- Ulinastatin 2.4 million units per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3- Ulinastatin 1.2 million units per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ulinastatin</intervention_name>
    <description>Patients will receive the study drugs for 7 to 14 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>UTI</other_name>
    <other_name>urinary trypsin inhibitor</other_name>
    <other_name>bikunin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients will receive the placebo for 7 to 14 days</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have provided signed written informed consent form (ICF) from the patient or the
             patient's legal representative;

          2. Male or Female patients ≥18 years of age;

          3. ARDS defined with using 2012 Berlin Criteria;

          4. ARDS diagnosed ≤72 hours, and patients should be mechanically ventilated (invasive
             and or noninvasive mechanical ventilation); 5)100mmhg &lt; PaO2/FiO2 &lt; 250mmhg with
             CPAP/PEEP≥5 cmH2O.

        Exclusion Criteria:

          1. Patient with known hypersensitivity to Ulinastatin/adjuvant or patient with allergic
             constitution;

          2. Presence or 2 or more extra-pulmonary failing organs failure according to SOFA；

          3. Cardiogenic pulmonary edema , and the cardiogenic pulmonary edema is as the only or
             primary reason for respiratory failure；

          4. Patients with severe fungal infection and or septic shock;

          5. ARDS caused by burning, drowning, poisoning;

          6. Presence of severe chronic liver diseases (Child-Pugh score 12-15)，or severe chronic
             respiratory disease with a PaCO2 &gt; 50 mmHg or the use of home oxygen;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yimin Li, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ming Jia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital, Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yihua Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zongan Liang</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital,Sichuan Unversity</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Huaxue Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital Bengbu Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 28, 2017</lastchanged_date>
  <firstreceived_date>July 21, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinastatin</mesh_term>
    <mesh_term>Trypsin Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
